Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.79 |
| ▸ | DRD3 | P35462 | 13/20 | 0.79 |
| ▸ | DRD4 | P21917 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | HTR1A | P08908 | 1/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.77 |
| ▸ | CASP1 | P29466 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2699679 | 0.90 | DRD2 (0.72) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL10075562 | 0.89 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL30350412 | 0.89 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL3030252 | 0.89 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL7568447 | 0.88 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL29448457 | 0.88 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL623950 | 0.88 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL8930123 | 0.88 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL29460204 | 0.88 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| Bromide SCHEMBL4204027 | 0.87 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034877-B2 | Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | DRD3, DRD2, SLC6A3 | DRD2 2/4885DRD3 1/4885DRD4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.